# Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

> **NCT05477264** · PHASE2 · RECRUITING · sponsor: **Won Seog Kim** · enrollment: 38 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05477264
- **Lead sponsor:** Won Seog Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477264, "Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05477264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*